

## **CURRICULUM VITAE**

### **Personal information**

Surname: Florentin

Name: Matilda

Date of birth: 9/9/1981

Address: Apsaradon 12, Ioannina

Postal Code: 45221

Phone numbers: 00302651072068, 00306944662406

e-mail: [matildaflorentin@yahoo.com](mailto:matildaflorentin@yahoo.com)

### **Education**

1992-1999: American College ANATOLIA

Graduate GPA: 19.3/20 (excellent)

1999-2005: School of Medicine, University of Ioannina

Graduate GPA: 8.85/10 (rank 4<sup>th</sup>)

### **Awards**

1999: Anatolia College award for the English language

2003: Institution of National Scholarships Award for top academic attendance and scoring for the academic year 2003-2004 (University of Ioannina, School of Medicine)

2004: Institution of National Scholarships Award for top academic attendance and scoring for the academic year 2004-2005 (University of Ioannina, School of Medicine)

2004: Award for top academic attendance and scoring for the Pathology course (University of Ioannina, School of Medicine)

2005: Institution of National Scholarships Award for top academic attendance and scoring for the academic year 2005-2006 (University of Ioannina, School of Medicine)

### **Languages**

Greek (native)

English (excellent)

German (excellent)

### **Diplomas**

1999: Certificate of English Proficiency (Anatolia College)

2004: Kleines Deutsches Sprachdiplom (KDS) (Goethe Institut)

### **Clinical experience**

Internal medicine, University Hospital of Ioannina, Greece (8 weeks)

General Surgery, University Hospital of Ioannina, Greece (8 weeks)

Paediatrics, University Hospital of Ioannina, Greece (8 weeks)

Obstetrics- Gynaecology, University Hospital of Ioannina, Greece (8 weeks)

Neurology, University Hospital of Ioannina, Greece (8 weeks)

Psychiatry, University Hospital of Ioannina, Greece (8 weeks)

September 2005-June 2006: Assistant Fellow in the Ippokrateion Hospital of Thessaloniki.

July 2006: I worked as a doctor in a summer camp.

January 2007-August 2009: Research Fellow in the Outpatient Lipid and Obesity Clinic of the University Hospital of Ioannina

September 2009-February 2010: Honorary Clinical Research Fellow in the Department of Clinical Biochemistry in Royal Free Hospital (Academic Head of the Department: Dimitri P Mikhailidis) (scholarship from the “Hellenic Atherosclerosis Society”)

March 2010-December 2015: Internship in Internal Medicine in the University Hospital of Ioannina

June 2016- University Fellow in University of Ioannina

**PhD:** “Efficacy of treatment with rimonabant alone or in combination with lipid lowering drugs in the metabolic parameters of overweight/obese patients with dyslipidemia”

I have participated and I am currently participating as investigator in several clinical studies associated with dyslipidemia and diabetes:

1. A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, FORCED-TITRATION STUDY TO COMPARE THE EFFICACY AND SAFETY OF THE COMBINATION OF 145 MG FENOFIBRATE AND 20 OR 40 MG SIMVASTATIN WITH 40 MG PRAVASTATIN MONOTHERAPY IN PATIENTS WITH MIXED DYSLIPIDEMIA AT RISK OF CARDIOVASCULAR DISEASE NOT ADEQUATELY CONTROLLED BY 40 MG PRAVASTATIN ALONE (NCT00362206)
2. THE STABILISATION OF ATHEROSCLEROTIC PLAQUE BY INITIATION OF DARAPLADIB THERAPY (GRS019)
3. A MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY OF THE CO-ADMINISTRATION OF SITAGLIPTIN AND PIOGLITAZONE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE INADEQUATE GLYCEMIC CONTROL (MK-0431)
4. AN EIGHT WEEK DOUBLE-BLIND, MULTICENTER, RANDOMIZED, MULTIFACTORIAL, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALISKIREN ADMINISTERED ALONE AND IN COMBINATION WITH AMLODIPINE IN PATIENTS WITH ESSENTIAL HYPERTENSION (SPA 100/ALISKIREN+AMLDIPINE, CSPA 100A2305)
5. A EUROPEAN RANDOMIZED, PARALLEL GROUP, TWO-ARM PLACEBO CONTROLLED, DOUBLE BLIND MULTICENTER STUDY OF RIMONABANT 20MG ONCE DAILY IN THE TREATMENT OF ABDOMINALLY OBESE PATIENTS WITH DYSLIPIDEMIA WITH OR WITHOUT OTHER COMORBIDITIES
6. EPIDEMIOLOGICAL STUDY OF EUROPEAN CARDIOVASCULAR RISK PATIENTS : DISEASE PREVENTION AND MANAGEMENT IN USUAL DAILY PRACTICE (EURIKA)

7. A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY ASSESSING THE IMPACT OF ADDITIONAL LDL-CHOLESTEROL REDUCTION ON MAJOR CARDIOVASCULAR EVENTS WHEN AMG 145 IS USED IN COMBINATION WITH STATIN THERAPY IN PATIENTS WITH CLINICALLY EVIDENT CARDIOVASCULAR DISEASE
8. A 24-WEEK, MULTICENTER, RANDOMIZED, OPEN-LABEL, 2ARM PARALLEL-GR STUDY EVALUATING THE EFFICACY AND SAFETY OF PATIENT-VERSUS PHYSICIAN-MANAGED TITRATION OF INSULIN GLARGINE U300 IN TYPE 2 DIABETES MELLITUS
9. THE EFFECT OF MEDICATION WITH PITAVASTATIN OR ATORVASTATIN ON THE SERUM GLUCOSE LEVELS OF PATIENTS HAVING MODERATE TO SEVERE RISK FOR ONSET OF DIABETES MELLITUS - "PAGODA"
10. EVALUATION OF THE TUBULAR EFFECTS OF DAPAGLIFLOZIN USING <sup>1</sup>H NMR SPECTROSCOPY

### **Publications**

1. **Florentin M**, Elisaf MS, Rizos CV, Nikolaou V, Bilianou E, Pitsavos C, Liberopoulos EN. L-Carnitine/Simvastatin Reduces Lipoprotein (a) Levels Compared with Simvastatin Monotherapy: A Randomized Double-Blind Placebo-Controlled Study. *Lipids* 2017;52:1-9
2. Filippatos TD, **Florentin M**, Georgoula M, Elisaf MS. Pharmacological management of diabetic dyslipidemia. *Expert Rev Clin Pharmacol.* 2017;10:187-200
3. **Florentin M**, Kostapanos MS, Kei A, Elisaf MS. Emerging drugs for hyperlipidaemia: an update. *Expert Opin Emerg Drugs* 2014;19:471-88
4. **Florentin M**, Liamis G, Elisaf MS. Colonoscopy preparation-induced disorders in renal function and electrolytes. *World J Gastrointest Pharmacol Ther* 2014;5:50-4
5. Kostapanos M, **Florentin M**, Elisaf MS, Mikhailidis DP. Hemostatic Factors and the Metabolic Syndrome. *Curr Vasc Pharmacol* 2013;11:880-905

6. Kostapanos MS, **Florentin M**, Elisaf MS. Fenofibrate and the kidney: an overview. *Eur J Clin Invest* 2013;43:522-31
7. \*Tsimihodimos V, **Florentin M**, Elisaf MS. How should we treat hypertension and dyslipidemia in patients with prediabetes? *Curr Pharm Des* 2013;19:3773-87
8. Lioudaki E, **Florentin M**, Ganotakis ES, Mikhailidis DP. Microalbuminuria: a neglected cardiovascular risk factor in non-diabetic individuals? *Curr Pharm Des*. 2013;19:4964-80
9. Kostapanos MS, **Florentin M**, Elisaf MS. Gender differences in the epidemiology, clinical presentation, prevention, and prognosis of acute coronary syndromes. *Angiology* 2013;64:5-8
10. Catapano AL, Elisaf MS, **Florentin M**, Mikhailidis DP, Kostapanos MS. Achieving Current Goals in Prevention and Treatment of Vascular Disease: An Update. *Curr Pharm Des* 2013;19:3749-52
11. **Florentin M**, Liberopoulos EN, Rizos CV, Kei AA, Liamis G, Kostapanos MS, Elisaf MS. Colesevelam plus rosuvastatin 5 mg/day versus rosuvastatin 10 mg/day alone on markers of insulin resistance in patients with hypercholesterolemia and impaired fasting glucose. *Metab Syndr Relat Disord*. 2013;11:152-6
12. Makariou S, Liberopoulos E, **Florentin M**, Lagos K, Gazi I, Challa A, Elisaf M. The relationship of vitamin D with non-traditional risk factors for cardiovascular disease in subjects with metabolic syndrome. *Arch Med Sci* 2012;8:437-43
13. Athyros VG, Elisaf MS, Alexandrides T, Achimastos A, Ganotakis E, Bilianou E, Karagiannis A, Liberopoulos EN, Tziomalos K, Mikhailidis DP; Assessing the Treatment Effect in Metabolic Syndrome Without Perceptible Diabetes (ATTEMPT) Collaborative Group. Long-term impact of multifactorial treatment on new-onset diabetes and related cardiovascular events in metabolic syndrome: a post hoc ATTEMPT analysis. *Angiology*. 2012;63:358-66 (as investigator of the ATTEMPT study)
14. Moutzouri E, Liberopoulos EN, **Florentin M**, Liamis G, Elisaf MS. Effects of statin monotherapy versus statin plus ezetimibe combination on serum uric acid levels. *J Cardiovasc Pharmacol Ther* 2012;18:13-8

15. **Florentin M**, Elisaf MS. Proton pump inhibitor (PPI)-induced hypomagnesemia: a new challenge. *World J Nephrol* 2012;1:151-4
16. **Florentin M**, Elisaf MS. Simvastatin interactions with other drugs. *Expert Opin Drug Saf* 2012;11:439-44
17. Athyros VG, Gossios TD, Tziomalos K, **Florentin M**, Karagiannis A, Mikhailidis DP. Is there an additional benefit from coronary revascularization in diabetic patients with acute coronary syndromes or stable angina who are already on optimal medical treatment? *Arch Med Sci*. 2011 Dec 31;7:1067-75
18. Kei A, **Florentin M**, Elisaf M, Liberopoulos E. Anticoagulant drugs: what is new? *Int Angiol*. 2011;30:299-320
19. Athyros VG, Karagiannis A, Ganotakis ES, Paletas K, Nicolaou V, Bacharoudis G, Tziomalos K, Alexandrides T, Liberopoulos EN, Mikhailidis DP; Assessing The Treatment Effect in Metabolic syndrome without Perceptible diabetes (ATTEMPT) Collaborative Group. Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study. *Curr Med Res Opin*. 2011;27:1659-68 (as investigator of the ATTEMPT study)
20. Athyros VG, Ganotakis E, Kolovou GD, Nicolaou V, Achimastos A, Bilianou E, Alexandrides T, Karagiannis A, Paletas K, Liberopoulos EN, Tziomalos K, Petridis D, Kakafika A, Elisaf MS, Mikhailidis DP; Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible Diabetes (ATTEMPT) Collaborative. Assessing the treatment effect in metabolic syndrome without perceptible diabetes (ATTEMPT): a prospective-randomized study in middle aged men and women. *Curr Vasc Pharmacol* 2011;9:647-57 (as investigator of the ATTEMPT study)
21. Athyros VG, Elisaf MS, Alexandrides T, Achimastos A, Ganotakis E, Bilianou E, Karagiannis A, Liberopoulos EN, Tziomalos K, Mikhailidis DP; Assessing the Treatment Effect in Metabolic Syndrome Without Perceptible Diabetes (ATTEMPT) Collaborative Group. Long-term impact of multifactorial treatment on new-onset diabetes and related cardiovascular events in metabolic syndrome: a post hoc ATTEMPT analysis. *Angiology*. 2012;63:358-66 (as investigator of the ATTEMPT study)

22. "European Panel on Low Density Lipoprotein (LDL) Subclasses": A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subclasses. Mikhailidis DP, Elisaf MS, Rizzo M, Berneis K, Griffin B, Zambon A, Athyros V, de Graaf J, März W, Parhofer KG, Rini GB, Spinas GA, Tomkin GH, Tselepis AD, Wierzbicki AS, Winkler K, **Florentin M**, Liberopoulos EN. *Curr Vasc Pharmacol* 2011s;9:533-71
23. "European Panel on Low Density Lipoprotein (LDL) Subclasses": A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subclasses: Executive Summary. Mikhailidis DP, Elisaf MS, Rizzo M, Berneis K, Griffin B, Zambon A, Athyros V, de Graaf J, März W, Parhofer KG, Rini GB, Spinas GA, Tomkin GH, Tselepis AD, Wierzbicki AS, Winkler K, **Florentin M**, Liberopoulos EN. *Curr Vasc Pharmacol* 2011;9:531-2
24. Association of Helicobacter pylori infection with cardiovascular disease-is it just a myth? Christodoulou DK, Milionis HJ, Pappa P, Katsanos KH, Sigounas D, **Florentin M**, Elisaf M, Tsianos EV. *Eur J Intern Med.* 2011 ;22:191-4
25. Combining rosuvastatin with sartans of different peroxisome proliferator-activated receptor- $\gamma$  activating capacity is not associated with different changes in low-density lipoprotein subfractions and plasma lipoprotein-associated phospholipase A(2). Rizos CV, Liberopoulos EN, Tellis CC, **Florentin M**, Elisaf MS, Tselepis AD. *Metab Syndr Relat Disord Metab Syndr Relat Disord.* 2011;9:217-23
26. Emerging options in the treatment of dyslipidemias: a bright future? **Florentin M**, Liberopoulos EN, Mikhailidis DP, Elisaf MS. *Expert Opin Emerg Drugs* 2011;16:247-70
27. Pleiotropic effects of nicotinic acid: beyond high density lipoprotein cholesterol elevation. **Florentin M**, Liberopoulos EN, Kei A, Mikhailidis DP, Elisaf MS. *Curr Vasc Pharmacol.* 2011;9:385-400
28. The effect of simvastatin alone versus simvastatin plus ezetimibe on the concentration of small dense low-density lipoprotein cholesterol in subjects with primary hypercholesterolemia. **Florentin M**, Liberopoulos EN, Moutzouri E, Rizos CV, Tselepis AD, Elisaf MS. *Curr Med Res Opin.* 2011;27:685-92

29. Review: Antiplatelet drugs: what comes next? Kei AA, **Florentin M**, Mikhailidis DP, Elisaf MS, Liberopoulos EN. *Clin Appl Thromb Hemost.* 2011;17:9-26
30. Vitamin D and metabolic syndrome: is there a link? **Florentin M**, Elisaf MS, Mikhailidis DP, Liberopoulos EN. *Curr Pharm Des.* 2010;16:3417-34
31. Comparison of hemoglobin A1c and fasting glucose criteria to diagnose diabetes among people with metabolic syndrome and fasting glucose above 100 mg/dL (5.5 mmol/L). Liberopoulos EN, **Florentin M**, Kei A, Mountzouri E, Agouridis A, Elisaf MS. *J Clin Hypertens (Greenwich).* 2010;12:543-8
32. The effect of antihypertensive agents on insulin sensitivity, lipids and haemostasis. Karagiannis A, Tziomalos K, Anagnostis P, Gossios TD, **Florentin M**, Athyros VG, Mikhailidis DP. *Curr Vasc Pharmacol.* 2010;8:792-803
33. Fenofibrate in primary biliary cirrhosis: a pilot study. Liberopoulos EN, **Florentin M**, Elisaf MS, Mikhailidis DP, Tsianos E. *Open Cardiovasc Med J.* 2010;4:120-6
34. Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study. Rizos CV, Milionis HJ, Kostapanos MS, **Florentin M**, Kostara CE, Elisaf MS, Liberopoulos EN. *Clin Ther.* 2010;32:492-505
35. Aliskiren, a direct renin inhibitor, in clinical practice: a new approach in the treatment of hypertension. Mountzouri E, **Florentin M**, Elisaf MS, Mikhailidis DP, Liberopoulos EN. *Curr Vasc Pharmacol.* 2010;8:344-62
36. Effect of non-statin lipid lowering and anti-obesity drugs on LDL subfractions in patients with mixed dyslipidaemia. **Florentin M**, Tselepis AD, Elisaf MS, Rizos CV, Mikhailidis DP, Liberopoulos EN. *Curr Vasc Pharmacol.* 2010;8:820-30
37. Vitamin D and cardiovascular disease: a novel agent for reducing cardiovascular risk? Anagnostis P, Athyros VG, Adamidou F, **Florentin M**, Karagiannis A. *Curr Vasc Pharmacol.* 2010;8:720-30
38. Statin loading in patients undergoing percutaneous coronary intervention for acute coronary syndromes: a new pleiotropic effect? Athyros VG, Tziomalos



- K, **Florentin M**, Karagiannis A, Mikhailidis DP. *Curr Med Res Opin.* 2010;26:839-42
39. A patient with new-onset hypercholesterolemia. Liberopoulos EN, **Florentin M**, Siamopoulos KC, Elisaf M. *J Clin Lipidol.* 2009;3:143-5
40. Effects of rimonabant, as monotherapy and in combination with fenofibrate or ezetimibe, on plasma adipokine levels: a pilot study. **Florentin M**, Liberopoulos EN, Tellis CC, Derdemezis CS, Elisaf M, Tselepis A. *Angiology.* 2010; 61:365-71
41. Drug combinations for dyslipidemia and obesity treatment in metabolic syndrome. **Florentin M**, Elisaf MS, Mikhailidis DP, Liberopoulos EN. *Curr Pharm Des* 2008;14:574-87
42. Efficacy and safety of ezetimibe plus orlistat or rimonabant in statin-intolerant nondiabetic overweight/obese patients with dyslipidemia. **Florentin M**, Kostapanos MS, Nakou ES, Elisaf M, Liberopoulos EN. *J Cardiovasc Pharmacol Ther.* 2009;14:274-82
43. Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality. Liberopoulos EN, **Florentin M**, Mikhailidis DP, Elisaf MS. *Expert Opin Drug Saf* 2008;7:717-25
44. Effect of rimonabant, micronised fenofibrate and their combination on cardiometabolic risk factors in overweight/obese patients: a pilot study. **Florentin M**, Liberopoulos EN, Filippatos TD, Kostara C, Tselepis A, Mikhailidis DP, Elisaf MS *Expert Opin Pharmacother* 2008;9:2741-50
45. Metabolic syndrome and Alzheimer's disease: a link to a vascular hypothesis? Milionis HJ, **Florentin M**, Giannopoulos S. *CNS Spectr* 2008;13:606-613
46. Multiple actions of high-density lipoprotein. **Florentin M**, Liberopoulos EN, Wierzbicki AS, Mikhailidis DP. *Curr Opin Cardiol* 2008;23:370-8
47. Sitagliptin in clinical practice: a new approach in the treatment of type 2 diabetes. **Florentin M**, Liberopoulos EN, Mikhailidis DP, Elisaf MS. *Expert Opin Pharmacother.* 2008;9:1705-20
48. Colesevelam hydrochloride in clinical practice: a new approach in the treatment of hypercholesterolaemia. **Florentin M**, Liberopoulos EN, Mikhailidis DP, Elisaf MS. *Curr Med Res Opin.* 2008;24: 995-1009

49. Persistent effect of Zoledronic Acid in Paget's disease. Tziomalos K., **Florentin M.**, Krikis N., Perifanis V., Karagiannis A., Harsoulis F; Clin Exp Rheumatol. 2007; 25:464-6
50. Fibrate-associated adverse effects beyond muscle and liver toxicity. **Florentin M.**, Liberopoulos EN, Mikhailidis DP, Elisaf MS. Curr Pharm Des. 2008;14:574-87
51. Ezetimibe-associated adverse effects: what the clinician needs to know. **Florentin M.**, Liberopoulos EN, Elisaf MS. Int J Clin Pract. 2008;62:88-96
52. Sibutramine-associated adverse effects: a practical guide for its safe use. **Florentin M.**, Liberopoulos EN, Elisaf MS. Obes Rev 2008;9:378-87
53. The role of renin-angiotensin system inhibition in the treatment of hypertension in the metabolic syndrome: are all the angiotensin receptor blockers equal? Karagiannis A., Mikhailidis DP., Athyros VG., Kakafika AI., Tziomalos K., Liberopoulos EN., **Florentin M.**, Elisaf M.; Expert Opin Ther Targets. 2007;11:191-205
54. Eplerenone relieves spironolactone-induced painful gynecomastia in a patient with primary aldosteronism. A. Karagiannis, K. Tziomalos, A. Kakafika, **M. Florentin**, VG. Athyros; Nephrol Dial Transplant. 2007;22:293
55. Dry cough as first manifestation of giant-cell arteritis. Karagiannis A., Mathiopoulou L., Tziomalos K., Kontotasios K., Skaperdas A., **Florentin**, Amlianitis IK, Athyros V.; J Am Geriatr Soc. 2006;54:1957-8
56. Angioedema may not be a class side effect of the angiotensin- converting-enzyme inhibitors. Karagiannis A., Pyrpasopoulou A., Tziomalos K., **Florentin M.**, Athyros V.; QJM 2006; 99: 197-198

\* I was Guest Editor of the Special Issue of *Current Pharmaceutical Design* entitled "Achieving Current Goals in Prevention and Treatment of Vascular Disease: an update" (general title of the issue: "New Developments in the Prevention and Treatment of Vascular Disease – 4").

Tsimihodimos V. and **Florentin M.** Hypertension and Dyslipidemia in Patients with Pre-Diabetes: Dietary and Other Therapies. In: "Glucose Intake and Utilization in Pre-Diabetes and Diabetes. Implications for Cardiovascular disease". Edited by Ronald Ross Watson and Betsy B. Dokken, Elsevier 2015.

## **Educational courses**

1. 2002: Greek Red Cross, First Aid lessons
2. 2003: Workshop entitled “*Medical Urgencies*” which was organized by the Anaesthesiology Clinic of the Medical School of the University of Ioannina
3. 2004: ESO Oncology for Medical Students, Ioannina, Greece
4. 2005: British Council Seminar on Medical Specialist Training in the UK
5. 2006: Educational Lessons in Endocrinology, Thessaloniki (award for top scoring in multiple question examination)
6. “Strategies in Diabetes mellitus 2008” organized by the Greek Diabetes Association and the European Association for the Study of Diabetes (12 CME credits), Loutraki Korinthias, Greece
7. “Simulation in Cardiovascular Emergency Cases”, 8/6/2008, Ioannina
8. 2008: Summer School “Atherosclerosis-Cardiovascular Disease: From pathophysiology to Clinical Practice” (15 CME credits), Athens, Greece
9. 2007-2008: Internet-based Educational Lessons of Hellenic Society for the Study of Bone Metabolism
10. 2007-2008: Internet-based Educational Lessons of Hellenic Society of Diabetes
11. 2008-2009: Internet-based Educational Lessons of Hellenic Society for the Study of Bone Metabolism
12. Future Lipid-Field Leaders Meeting (Genzyme meeting), Belgium, 11-12/12/09
13. MECHOLAB (Mediterranean CHolestagel Advisory Board), Nice, France, 29/2/08- 1/03/08
14. “Comprehensive evaluation of a journal paper: Critical appraisal of a randomized controlled trial”, 13/11/09, Royal Free Hospital, London, UK
15. “Comprehensive evaluation of a journal paper: Critical appraisal of a systematic review”, 10/12/09, Royal Free Hospital, London, UK
16. “Strategies in Diabetes mellitus 2010” organized by the Greek Diabetes Association and the European Association for the Study of Diabetes (13 CME credits), 22-24/4/2010, Kamena Vourla, Greece
17. “Educational Seminar in Thrombosis and Anti-thrombotic therapy” (9 CME credits from European Accreditation Council for Continuing Medical Education), 4-5/11/11, Ioannina, Greece

18. 2<sup>nd</sup> Greek Congress of the “Institute for the study of Diabetes Mellitus and Metabolic Diseases” (3<sup>rd</sup> award for the study: “Co-administration of L-carnitine with simvastatin reduces lipoprotein (a) levels compared with simvastatin monotherapy: a randomised double-blind placebo-controlled study”. Liberopoulos E, Nikolaou V, Pitsavos C, Bilianou E, **Florentin M**, Elisaf M), 27-29/4/12, Athens, Greece
19. “Strategies in Diabetes mellitus 2012” organized by the Greek Diabetes Association and the European Association for the Study of Diabetes (12 CME credits), 17-19/5/2012, Loutraki Korinthias, Greece
20. “2<sup>nd</sup> Educational Seminar in Thrombosis and Anti-thrombotic therapy” (9 CME credits from European Accreditation Council for Continuing Medical Education), 9-10/11/12, Ioannina, Greece
21. **ALS PROVIDER COURSE** (issued by European Resuscitation Council), 6-7/2/2016, Ioannina, Greece
22. EAS Advanced Course on “Crossroads of Atherosclerosis-Immunology-Lipids”, 22-25/3/2016, Amsterdam, the Netherlands
23. 84<sup>th</sup> EAS Congress, 29/5/2016-1/6/2016, Innsbruck, Austria. Participation in the Congress, including EBAC-accredited programme "Low HDL high triglyceride, diabetic dyslipidaemia" and EBAC-accredited programme “Diet and prevention of cardiovascular disease”
24. 9<sup>th</sup> School of Clinical Hepatology, under the auspices of Hellenic Association for the study of the liver (25 CME-CPD credits)

### **Participation in Congresses**

1. Effect of treatment with rimonabant alone or together with fenofibrate or ezetimibe on anthropometric and lipid parameters in obese dyslipidemic patients. **Matilda Florentin**, Evangelos Liberopoulos, Christos Rizos, Christos Derdemezis, Moses Elisaf. Balkan Congress of Obesity. Thessaloniki, 17-19/10/2008
2. Ezetimibe in combination with orlistat or rimonabant in overweight/obese patients with dyslipidemia and a history of statin-intolerance. **M. Florentin**, E. Liberopoulos, M. Kostapanos, C. Kostara, E. Nakou, M. Elisaf. Prediabetes and the metabolic syndrome, Nice, France, 1-4/4/2009

3. Co-administration of sartans with different degree of PPAR $\gamma$  activating capacity plus rosuvastatin in patients with multiple metabolic risk factors. C. Rizos, E. Liberopoulos, **M. Florentin**, H. Milionis, M. Elisaf. Prediabetes and the metabolic syndrome, Nice, France, 1-4/4/2009
4. The effect of simvastatin versus combined simvastatin/ezetimibe treatment on the concentration of small dense low-density lipoprotein particles in patients with primary hypercholesterolemia. **M. Florentin**, E. Liberopoulos, E. Moutzouri, C. Rizos, C. Kostara, A. Tselepis, M. Elisaf. 4th Panhellenic Atherosclerosis Congress, 13-16/10/2010, Ioannina, Greece (Award)
5. Colesevelam with low-dose statin is associated with a favorable effect on markers of insulin resistance compared with a higher dose statin. **M. Florentin**, E. Liberopoulos, A.A. Kei, C.V. Rizos, M. S. Elisaf. 81<sup>st</sup> EAS Congress, Lyon, France, 2-5/6/2013

I participated as an Assistant in the 'European Panel on Atherogenic LDL subfractions', held in Athens on 5th of December, 2009.

### **Career plan**

I finished my internship 1,5 year ago and successfully passed the final exams in *Internal Medicine* in the Department of Internal Medicine of the University Hospital of Ioannina.

I have also presented my PhD which deals with effects of rimonabant and several lipid-lowering drugs on metabolic parameters in overweight and obese patients with dyslipidemia.

My current research interests include dyslipidemia, diabetes, hypertension and obesity.